Information Provided By:
Fly News Breaks for November 15, 2019
Nov 15, 2019 | 07:04 EDT
Cantor Fitzgerald analyst Kristen Kluska assumed coverage of Rigel Pharmaceuticals and maintained an Overweight rating on the shares with a price target of $5, down from $7. The analyst thinks Rigel is set up to execute positively in 2020.
News For RIGL From the Last 2 Days
There are no results for your query RIGL